Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 20,000 Shares of Stock

Key Points

• Insider James Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals at an average price of $35.00, totaling $700,000, which reduced his ownership by 8.62%.
• The stock traded up 4.4% to reach $36.12, with a market capitalization of $4.99 billion and a 52-week range from $9.57 to $36.24.
• Despite reporting earnings of ($1.26) EPS, which missed analysts' estimates, Arrowhead has received multiple upgrades and maintains an average rating of "Moderate Buy" with a consensus target price of $43.14.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James Hamilton sold 20,000 shares of the business's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider owned 212,122 shares in the company, valued at $7,424,270. This trade represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Arrowhead Pharmaceuticals Trading Up 4.4%

NASDAQ:ARWR traded up $1.52 on Friday, reaching $36.12. 1,957,497 shares of the company's stock were exchanged, compared to its average volume of 2,071,932. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $4.99 billion, a price-to-earnings ratio of -28.22 and a beta of 1.12. The business has a fifty day moving average of $24.13 and a 200-day moving average of $18.02. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $36.24.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the previous year, the business earned ($1.38) EPS. As a group, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of recent research reports. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Royal Bank Of Canada cut their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $43.14.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 64.4% in the third quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company's stock valued at $91,000 after acquiring an additional 1,029 shares during the period. Corient Private Wealth LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $269,000. Texas Permanent School Fund Corp acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $302,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Arrowhead Pharmaceuticals by 9.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 27,737 shares of the biotechnology company's stock valued at $438,000 after acquiring an additional 2,444 shares during the period. Finally, Marex Group plc acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $576,000. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.